Synthetic carbohydrate derivatives as low sulfated heparin mimetics

被引:9
作者
Driguez, PA [1 ]
Lederman, I [1 ]
Strassel, JM [1 ]
Herbert, JM [1 ]
Petitou, M [1 ]
机构
[1] Sanofi Synthelab, F-31036 Toulouse, France
关键词
D O I
10.1021/jo991152j
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The total synthesis of a new family of heparin mimetics containing an hexadeca- (2), an octadeca- (3), and an eicosasaccharide (4) is described. All three oligosaccharides contain a pentasaccharidic antithrombin binding domain(DEFGH: van Boeckel, C. A. A.; Petitou, M. Angew. Chem., Int. Ed. Engl. 1993, 32, 1671-1690), extended at the nonreducing end by a thrombin binding domain composed of repeated 2,3-di-O-methyl-6-O-sodium sulfonato-alpha-D-glucosyl units, The targets were synthesized using a key dodecasaccharide imidate as glycosyl donor as well as di- and tetrasaccharide imidates, all derived from maltose. Condensation of these imidates with a tetrasaccharide precursor of the EFGH part of the antithrombin binding domain gave fully protected hexadeca-, octadeca-, and eicosasaccharide that were deprotected and sulfated to yield 2, 3, and 4. All three displayed antithrombin-mediated antifactor Xa and antithrombin (factor IIa) activity. The most active compound, the eicosasaccharide, showed activity similar to that of low molecular weight heparin. Significantly, unlike heparin and its derivatives, the present: heparin mimetics do not interact with platelet factor 4, an interaction that can cause severe side effects in heparin-treated patients. Thus, this new family of compounds contains interesting drug candidates for the prevention and treatment of thrombosis.
引用
收藏
页码:9512 / 9520
页数:9
相关论文
共 18 条
[1]   STRUCTURE AND BIOLOGICAL-ACTIVITY OF HEPARIN [J].
CASU, B .
ADVANCES IN CARBOHYDRATE CHEMISTRY AND BIOCHEMISTRY, 1985, 43 :51-134
[2]   Design and synthesis of heparin mimetics able to inhibit thrombin. Part 1 - Identification of a hexasaccharide sequence able to inhibit thrombin and suitable for 'polymerisation' [J].
Duchaussoy, P ;
Jaurand, G ;
Driguez, PA ;
Lederman, I ;
Gourvenec, F ;
Strassel, JM ;
Sizun, P ;
Petitou, M ;
Herbert, JM .
CARBOHYDRATE RESEARCH, 1999, 317 (1-4) :63-84
[3]   Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition [J].
Duchaussoy, P ;
Jaurand, G ;
Driguez, PA ;
Lederman, I ;
Ceccato, ML ;
Gourvenec, F ;
Strassel, JM ;
Sizun, P ;
Petitou, M ;
Herbert, JM .
CARBOHYDRATE RESEARCH, 1999, 317 (1-4) :85-99
[4]   RATIONAL DESIGN OF SYNTHETIC HEPARIN ANALOGS WITH TAILOR-MADE COAGULATION-FACTOR INHIBITORY ACTIVITY [J].
GROOTENHUIS, PDJ ;
WESTERDUIN, P ;
MEULEMAN, D ;
PETITOU, M ;
VANBOECKEL, CAA .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (09) :736-739
[5]   2-(TRIMETHYLSILYL)ETHYL GLYCOSIDES .3. SYNTHESIS, ANOMERIC DEBLOCKING, AND TRANSFORMATION INTO 1,2-TRANS 1-O-ACYL SUGARS [J].
JANSSON, K ;
AHLFORS, S ;
FREJD, T ;
KIHLBERG, J ;
MAGNUSSON, G ;
DAHMEN, J ;
NOORI, G ;
STENVALL, K .
JOURNAL OF ORGANIC CHEMISTRY, 1988, 53 (24) :5629-5647
[6]  
LANE DA, 1989, HEPARIN
[7]   REGULATION OF THROMBIN ACTIVITY BY ANTITHROMBIN AND HEPARIN [J].
OLSON, ST ;
BJORK, I .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1994, 20 (04) :373-409
[8]   Synthetic oligosaccharides having various functional domains: Potent and potentially safe heparin mimetics [J].
Petitou, M ;
Driguez, PA ;
Duchaussoy, P .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (08) :1161-1166
[9]  
Petitou M, 1998, ANGEW CHEM INT EDIT, V37, P3009, DOI 10.1002/(SICI)1521-3773(19981116)37:21<3009::AID-ANIE3009>3.0.CO
[10]  
2-F